With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia ...

The US Food and Drug Administration (FDA) has approved Shorla Oncology’s Imkeldi oral solution to treat certain forms of ...

The Food and Drug Administration (FDA) has approved Shorla Oncology‘s IMKELDI for the treatment of specific leukaemia cancer ...

Detailed price information for Inhibikase Therapeutics Inc (IKT-Q) from The Globe and Mail including charting and trades.

Stivarga (BAY 73-4506) is the brand name for the generic chemotherapy agent regorafenib, an oral anticancer medication approved by the FDA for individuals with locally advanced, unresectable, or ...

In the case of IKT-001Pro, it is a modified novel version of imatinib [GLEEVEC], which failed to gain FDA approval for PAH because of major side effects. The company believes that it has solved ...

We believe IkT-001Pro, a prodrug of imatinib, has the potential to ameliorate the safety and tolerability profile that precluded approval of imatinib for the treatment of PAH more than 10 years ago.

The company has also filed an Investigational New Drug (IND) application for a Pro drug formulation of imatinib mesylate for PAH, with clinical development set to begin later this year.

Get detailed information on Garenoxacin Mesylate, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated ...